The new 3D technology - called EVATAR - is made with human tissue and will enable scientists to conduct much-needed testing of new drugs for safety and effectiveness on the female reproductive system.
EVATAR also will help scientists understand diseases of the female reproductive tract such as endometriosis, fibroids (which affect up to 80 per cent of women), cancer and infertility.
The ultimate goal is to use stem cells of an individual patient and create a personalised model of their reproductive system.
The organ models are able to communicate with each other via secreted substances, including hormones, to closely resemble how they all work together in the body.The organ models are able to communicate with each other via secreted substances, including hormones, to closely resemble how they all work together in the body.
"This will help us develop individualised treatments and see how females may metabolise drugs differently from males," said Teresa Woodruff, director of the Women's Health Research Institute at Northwestern University.
The model includes ovaries, the uterus, the fallopian tubes, the cervix and vagina. The liver was also included in the system because it metabolises drugs.
The microfluidic device has a series of cables and pumps that cause media (simulated blood) to flow between wells.
The technology also will open doors into the causes of endometriosis, fibroids and some cancers.
"All of these diseases are hormonally driven, and we really don't know how to treat them except for surgery," said Joanna Burdette, of University of Illinois at Chicago.
"The systems are tremendous for the study of cancer, which often is studied as isolated cells rather than system-wide cells. This is going to change the way we study cancer," Burdette said.
The system also will allow scientists to test millions of compounds in the environment and new pharmaceuticals to understand how they affect the reproductive system and many other organs in the body.
The paper was published March 28 in Nature Communications.
Disclaimer: No Business Standard Journalist was involved in creation of this content
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
